Researchers have reported that people with Down syndrome have 10 times the risk of dying from COVID-19, as compared to those without the disability, CNN reported on Friday.
The researchers also found a four-fold increased risk of COVID-19 related hospitalisations for those with Down syndrome, "a group that is not currently strategically protected," according to the report in the journal Annals of Internal Medicine.
The researchers have said: "This was after adjustment for cardiovascular and pulmonary diseases and care home residence, which our results suggest explained some but not all of the increased risk."
This analysis involved over eight million adults who were part of a COVID-19 risk assessment project sponsored by the British government. Of the 8.26 million people in the tracking study, 4,053 had Down syndrome. Of those, 68 people with the disability died and 40% were killed by COVID-19. Seventeen died of pneumonia or pneumonitis and 35% died of other causes.
Those numbers compare with more than 41,000 people without Down syndrome who died, but just 20% died from COVID-19, 14% from pneumonia or pneumonitis and 65% died of other causes.
Reportedly, Down syndrome is not included in any guidance from the US Centres for Disease Control and Prevention or the UK's health ministry as a condition that would put people at increased risk for COVID-19.
"However it is associated with immune dysfunction, congenital heart failure, and pulmonary pathology and, given its prevalence, may be a relevant albeit unconfirmed risk factor for severe Covid-19," the researchers concluded.
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China